ARCHIVES

Phase III Trial of Alimta, Avastin Combination Fails Endpoint to Improve Overall Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 9 | September 28, 2012

Download PDF Visit The Full Archive

Related Articles

Senate Confirms FDA Commissioner Von Eschenbach.

December 8, 2006

DCPC Bard Approves Concepts For New Minority Enhancement Awards Program, Two RFA Reissues

January 22, 1988

In Brief: William Peters To Leave Duke To Head Michigan Cancer Foundation, Prentis Center

April 7, 1995

NCCS Networker Volume 1 Issue 3, Fall 1987

September 13, 1987

ASCO Awards Contract For D.C. Office

January 5, 1990

Gore, Agency Report, Support Legislation To Protect Genetic Info

January 30, 1998